• SmithKline Beecham's chief scientific officer, George Poste, speaks of pharmacogenomics as the savior of the industry.

    FORBES: Tailor-made drugs

  • Among the first to recognize this potential was George Poste, former chief scientist for SmithKline Beecham.

    FORBES: Divining Disease

  • In 1996 SmithKline Beecham vowed to discover two new antibiotic classes by 2003.

    FORBES: Germ Warfare

  • Now, it is losing market share rapidly to competitors such as Pfizer's Zoloft and SmithKline Beecham's Paxil.

    ECONOMIST: Too clever by half

  • WHO, which is starting, in collaboration with Merck and SmithKline Beecham, a massive drug-donation programme for the disease.

    ECONOMIST: A poor diagnosis

  • Most drugs on the market today target such receptors: SmithKline Beecham's ulcer medicine Tagamet, and American Home Product's hypertension drug Inderal.

    FORBES: Rx: No merger

  • The hastily announced drug merger between Glaxo Wellcome and SmithKline Beecham collapsed when neither boss was prepared to pay second fiddle.

    ECONOMIST: After the deal

  • Two new giants were created in the drug industry : Glaxo Wellcome announced a union with SmithKline Beecham, and Pfizer completed its acquisition of Warner-Lambert.

    ECONOMIST: A growing world

  • In Britain, there is a well-worn path between drug giants such as SmithKline Beecham and Glaxo Wellcome, and executive and non-executive slots on biotech boards.

    ECONOMIST: European biotech: Management shortfall | The

  • Avandia was invented in the laboratories of Smithkline Beecham, a Glaxo predecessor, two decades ago as one of a class of medicines meant to treat diabetes.

    FORBES: Magazine Article

  • Wyeth-Ayerst, Abbott Laboratories, Merck, SmithKline Beecham and Pfizer have invested heavily in the field, either on their own or by buying or teaming up with smaller, entrepreneurial research outfits.

    FORBES: A hail of silver bullets

  • He instead joined SmithKline Beecham, the predecessor of GSK, in 1996 for the purpose of picking up the management experience he needed to head the next startup.

    FORBES: On The Cover/Top Stories

  • The U.S. arm of U.K. pharmaceutical firm SmithKline Beecham agreed in principle with a Cuban biotech institute to develop and market a meningitis vaccine created by the Cubans.

    FORBES: Give 'em rope

  • The U.S. arm of British pharmaceutical firm SmithKline Beecham agreed in principle with a Cuban biotech institute to develop and market a meningitis vaccine created by the Cubans.

    FORBES: Castro's props

  • The new combined vaccine, Hepatyrix, is marketed by SmithKline Beecham.

    BBC: Combined jab launched for holidaymakers

  • For one thing, there's Chief Financial Officer Andrew Bonfield , who previously worked as CFO at SmithKline Beecham, now part of GlaxoSmithKline (nyse: GSK - news - people ).

    FORBES: Magazine Article

  • Megamergers like Vodaphone's bid to buy Mannesmann in telecom and Glaxo Wellcome's embrace of SmithKline Beecham in drugs are reducing the supply of big, rich companies that can pay Spencer Stuart's hefty fees.

    FORBES: The Skin Game, Updated

  • To facilitate the restatement, New York City-based Bristol brought on a new chief financial officer, Andrew Bonfield Andrew Bonfield , who served as chief financial officer at SmithKline Beecham before it became part of GlaxoSmithKline .

    FORBES: Bristol's Big Tease

  • Dr Alistair Benbow, medical director of SmithKline Beecham, said that ropinirole was associated with sleepiness, but only in a tiny minority of patients, and that the company had never previously come across patients who experienced sudden sleep attacks.

    BBC: Parkinson's patients face sleep danger

  • There has also been speculation that the company, formed two years ago from a tie-up between the UK's Glaxo Wellcome and SmithKline Beecham, could be forced into further costly mergers or acquisitions in order to ensure future growth.

    BBC: Asthma drug inflates Glaxo profits

  • GSK's two predecessor companies, SmithKline Beecham and Glaxo Wellcome, which merged to form GSK in 2000, had been among the first to invest in gene-hunting technology that scientists once thought would fast lead to a bushelful of new drugs.

    FORBES: Magazine Article

  • Among his decisions are rulings upholding an insurance company's waiver of a particular defense, sending litigation involving Cigna back to England and one denying an award to a whistleblower who merely disclosed public information about SmithKline Beecham, now part of GlaxoSmithKline.

    FORBES: Magazine Article

  • To facilitate the restatement, New York City-based Bristol brought on a new chief financial officer, Andrew Bonfield , who served as chief financial officer at SmithKline Beecham before it became part of GlaxoSmithKline (nyse: GSK - news - people ).

    FORBES: Bristol's Big Tease

  • Among his decisions are rulings upholding an insurance company's waiver of a particular defense, sending litigation involving Cigna (nyse: CI - news - people ) back to England and one denying an award to a whistleblower who merely disclosed public information about SmithKline Beecham, now part of GlaxoSmithKline (nyse: GSK - news - people ).

    FORBES: Law And Order Guy

  • The consortium is a who's who of important pharmaceutical names: AstraZeneca azn (nyse: azn - news - people), Bristol-Myers Squibb bmy (nyse: bmy - news - people), Glaxo Wellcome glx (nyse: glx - news - people), Novartis nvs (nyse: nvs - news - people), Pfizer pfe (nyse: pfe - news - people)and SmithKline Beecham sbh (nyse: sbh - news - people).

    FORBES: Orchid Biosciences Not Yet In The Black

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定